MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$38.3M over 180 days (0 open-market buys, 87 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.7B— | $1.9B+14.9% | $2.3B+20.2% | $2.9B+23.6% | $3.2B+10.6% |
| EPS (dil.) | $10.06— | $15.00+49.1% | $19.81+32.1% | $24.64+24.4% | $27.86+13.1% |
| Free Cash Flow | $477M— | $664M+39.0% | $748M+12.6% | $1.1B+44.5% | $1.0B-3.7% |
| Gross Margin | 92.7% | 92.4%-0.3pp | 88.9%-3.5pp | 89.2%+0.3pp | 87.9%-1.3pp |
| Operating Margin | 33.0% | 50.6%+17.6pp | 50.9%+0.3pp | 47.9%-3.1pp | 47.7%-0.2pp |
| Net Margin | 28.2% | 37.6%+9.3pp | 42.3%+4.8pp | 41.5%-0.8pp | 41.9%+0.4pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 14.2%/yr (revenue basis).
Base free cash flow $956M (avg FY2023–FY2025; latest year $1.0B) · equity value $25.8B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Avg target $636 (last qtr, 10 analysts) → $690 (last mo, 8) (+8.6%).
Buy-rated share 80% → 73% over ~3 months (-7pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $6.86 | $7.27 | +6.0% |
| May 2026 | $7.00 | $5.82 | -16.9% |
| Feb 2026 | $7.13 | $7.70 | +8.0% |
| Oct 2025 | $6.89 | $7.16 | +3.9% |
| Jul 2025 | $7.29 | $6.41 | -12.1% |
| Apr 2025 | $6.29 | $6.63 | +5.4% |
| Feb 2025 | $6.40 | $6.19 | -3.3% |
| Oct 2024 | $6.43 | $6.39 | -0.6% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 53 for United Therapeutics Corporation suggests a neutral outlook, with the stock's strengths and weaknesses balancing out. The company scores high on profitability, driven by its strong ROE and operating margin, but is held back by its value and growth scores, which are impacted by its P/E of 19.9 and negative free cash flow growth. The stock exhibits strong momentum, with a 12-month return of 31.5%, but its short-term and long-term scores are relatively close, indicating a consistent outlook.